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ABSTRACT Mouse L cells transfected with a genomic clone
containing the H-2Ld gene (8-5 cells) were shown to function as
targets for H-2Ld-specific cytotoxic T lymphocytes (CTL). The
CTL-mediated lysis of 8-5 cells was shown to be H-2Ld specific
by the use of (i) CTL with restricted reactivity, (ii) unlabeled target
inhibition, and (iii) monoclonal antibody inhibition. We also dem-
onstrated that 8-5 cells could function as targets for antibody-plus-
complement-mediated cell lysis. Specificity was confirmed by us-
ing H-2Ld-specific monoclonal antibodies. These experiments
demonstrate that the gene products of a major histocompatibility
complex genomic clone can be functionally expressed in a foreign
cell and can mediate immunologically specific cellular interactions.
Early interest in the major histocompatibility complex (MHC)
derived from its role in the rejection ofallografts, cell-mediated
cytotoxic responses, and mixed lymphocyte reactions. It was
subsequently learned that such "unrestricted" allogeneic re-
actions are an exception among the array ofimmune responses;
immune cellular collaboration and T-cell specificity are gen-
erally restricted by recognition of self MHC determinants (1,
2). Thus it has become of interest to determine not only the
effects of manipulating alloimmune responses but also the ef-
fects of manipulating MHC determinants themselves.
Until now, immunogenetic analysis of the mouse MHC, H-
2, has been dependent upon the occurrence of intra-H-2 re-
combinants or MHC mutants as a source ofMHC variant cells.
Recently, however, the availability of cloned cDNA probes for
MHC antigens has allowed the isolation of several appropriate
genomic DNA clones from a BALB/c sperm DNA library (3).
One genomic clone, 27.5, was shown to contain the H-2Ld gene
by DNA-mediated gene transfer into mouse L cells (4). The
ability to place foreign H-2 molecules on the surface of cells by
means of transformation with cloned H-2 genes provides a
method of manipulating given H-2 genes in vitro and studying
the immune properties of their cell surface products after gene
transfer.
A rigorous correlation between 27.5 gene transfer and the
expression ofH-2Ld molecules has been established by the reac-
tivity of H-2Ld-specific monoclonal antibodies with the 27.5-
transfected L-cell clone, 8-5 (4). In order to determine whether
the H-2Ld molecule on 8-5 cells was expressed in a biologically
relevant way, we evaluated whether the H-2Ld product could
also be recognized by cytotoxic T lymphocytes (CTL). Here we
describe the recognition of the transferred gene product by H-
2d immune CTLs and provide further evidence that this product
is H-2Ld.
MATERIALS AND METHODS
Mice. CGH-2dm2 mice were generously supplied by Roger
Melvold (Northwestern University). All other mice were bred
and housed in the immunogenetics mouse colony at the Uni-
versity of Southern California Medical School.
Cell Lines. Two cell lines derived from C3H mouse L cells
(H-2k) were used. Ltk' cells were obtained by transfection of
thymidine kinase (TK)-negative (Ltk-) cells with the cloned
herpesvirus tk gene; 8-5 cells were obtained by cotransforma-
tion of Ltk- cells with the her esvirus tk gene and genomic
clone 27.5 containing the H-2L gene (4). Transformants were
selected and cloned in Dulbecco's modified Eagle's minimal
essential medium containing 10% fetal calf serum and hypo-
xanthine/aminopterine/thymidine (HAT medium). Both 8-5
and Ltk' were maintained in HAT medium as adherent cell
lines in 75-cm2 tissue culture flasks. Before use as targets, cells
were removed from the plastic by incubation with 0.02% trypsin
at 37°C for 3-5 min. Trypsin activity was terminated by the
addition of medium containing 10% fetal calf serum. The mas-
tocytoma P815 (H-2d) was maintained in RPMI-1640 with 10%
fetal calf serum.
Monoclonal Antibodies and Alloantisera. Monoclonal anti-
bodies 28-14-8S and 30-5-7S were supplied as ascites and were
the generous gift of David Sachs (National Institutes of Health).
They recognize specificities H-2.64 and H-2.65, respectively
(5). With H-2d mice, monoclonal 28-14-8S detects both H-2Ld
and H-2Rd molecules, whereas monoclonal 30-5-7S is reactive
with H-2Ld exclusively (6). Monoclonals 4-9.4, 5-7.1, 6-27.10,
7-16.20, 7-16.32, and 7-30.2 were produced in our laboratory
according to published techniques (7) and will be described in
detail elsewhere. Monoclonal 4-9.4 originated from a B10.P
anti-B10.Q immunization and has a haplotype distribution pat-
tern corresponding to specificity H-2.65 (reacts with H-2dq;
does not react with H_2b kf.P r S jdm2). That 4-9.4 reacts with
BALB/c but not CH-22dm2 cells indicates that it detects H-2Ld
or H-2Rd molecules or both; the results described in this manu-
script indicate that it recognizes at least H-2Ld products. Mono-
clonals 5-7.1, 6-27.10, 7-16.32, and 7-30.2 were selected as con-
trols on the basis of their reactivity with H-2Kd- or H-2Kk-
encoded determinants and their lack of activity with H-2D re-
gion-encoded products.
Abbreviations: Con A, concanavalin A; CTL, cytotoxic T lymphocyte;
HAT, hypoxanthine/aminopterin/thymidine; MHC, major histocom-
patibility complex; TK, thymidine kinase.
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The C-H-2dm2 anti-BALB/c antiserum used here was ob-
tained from Ted Hansen (Merck Sharp & Dohme, Rahway, NJ).
It has been tested on a panel of H-2 haplotypes and found to
exhibit weak cytotoxic activity (titer, 1:10) against H-2.64+, H-
2.65- strains and stronger activity (titer, 1:160) against H-2.64+,
H-2.65+ strains. No activity was detected against H-2.64-, H-
2.65- strains. All other antisera used were produced and char-
acterized in our laboratory by established techniques (8). The
serological reagents used and their specificities are described
in Table 1.
Serology. A complement-dependent cytotoxicity assay (9)
was used to detect foreign H-2 specificities on the surface of
8-5 cells. Selected rabbit serum was used as a complement
source. Mesenteric lymph node cells were isolated after sedi-
mentation with Lympholyte M (Cederlane Laboratories). Ltk+
and 8-5 cells were used directly after brief trypsinization and
washing. Complement control cytotoxicity was always <10%
with lymph node or Ltk+ targets. The 8-5 cells were more sen-
sitive to killing by complement, with backgrounds of <25%.
In Vitro Sensitization. Alloreactive cytotoxic T cells were
generated by standard techniques (10). Briefly, spleen cells
were depleted of erythrocytes, washed, and added to 25-cm2
tissue culture flasks at a concentration of 2.5 X 107 responders
and 2.5 x 107 irradiated [2,000 rads (1 rad = 0.01 gray)] stim-
ulators in 20 ml of Click's medium supplemented with 1% nor-
mal mouse serum. Sensitization flasks were cultured upright
in humidified 7.5% C02/92.5% air at 37°C for 5 days.
Chromium Release Assay. Effector cells or control cells (re-
sponders cultured with syngeneic stimulators) derived from 5-
day sensitization cultures were mixed with 1 x 104 51Cr-labeled
target cells in triplicate in round-bottomed microtiter plates
containing a total volume of 0.2 ml. Effector/target ratios
ranged from 100:1 to 6:1. Target cells were labeled by incu-
bation with sodium [51Cr]chromate (200-400 ,uCi/ml; 1 Ci =
3.7 X 1010 becquerels) for 1-2 hr at 37°C. Target cells consisted
of Ltk+ cells, 8-5 cells, P815 cells, or concanavalin A (Con A)-
induced lymphoblasts derived from normal mice ofvarious hap-
lotypes. Con A blasts were prepared by incubating splenic lym-
phocytes for 3 days at 37°C in RPMI medium supplemented
with antibiotics, 10% fetal calf serum, and Con A at 2 ,ug/ml.
Plates containing effectors and labeled targets were centrifuged
at 60 x g for 3 min and incubated at 37°C for 4 hr. Supernatants
were harvested by using the Titertek supernatant harvesting
system (Flow Laboratories, McLean, VA). Maximal releasable
51Cr was determined by distilled water lysis ofan equal number
of target cells. Spontaneous release was determined by incu-
bation oftarget cells with medium alone. Percentage chromium
Table 1. Reagents used and their relevant activities
Antiserum or Relevant H-2d or H-2k Serologic
monoclonal antibody molecules detected specificity
(AxBlO)Fi anti-BlO.D2 Kd H-2.31 (and others)
CH_2dn2 anti-BALB/c Ld and Rd H-2.64 and H-2.65
7-16.20 None H-2.37
7-16.32 Kk H-2.1
7-30.2 Kd Not assignedt
5-7.1 Kd Not assignedt
6-27.10 Kd Not assignedt
4-9.4 Ld (and Rd?) H-2.65
28-14-8S* Ldand Rd H-2.64
30-5-7S* Ld H-2.65
* These reagents have been characterized by Ozato et al. (5) and Han-
sen et al. (6).
tMonoclonals 7-30.2, 5-7.1, and 6-27.10 recognize previously unde-
fined specificities shared by Kd molecules.
release was calculated as:
experimental cpm - spontaneous release
maximal release - spontaneous release
In all cases, chromium release with control effector cells was
<5% and is not shown.
Unlabeled Target Inhibition. Unlabeled Con A blasts (block-
ers) were added at the beginning of the chromium release assay
in blocker/target ratios ranging from 20:1 to 2.5:1; the number
of target cells was held constant. Percentage inhibition was cal-
culated as:
% Cr release with blockers
% Cr release without blockers
Antisera/Monoclonal Antibody Inhibition. Various antisera
or monoclonal reagents were added at the initiation ofthe chro-
mium release assay in the dilutions shown in Fig. 5. Percentage
inhibition was calculated as:
% Cr release in the presence of antibody1- X 100.
% Cr release in the absence of antibody
RESULTS
Cell-Mediated Cytotoxicity. Goodenow et al. (4) described
the successful transfer of a genomic DNA clone, 27.5, contain-
ing the gene encoding the BALB/c H-2Ld molecule (11) into
mouse L cells. One of the clones (8-5) was shown to express H-
2Ld molecules virtually indistinguishable from spleen H-2Ld
molecules by two-dimensional gel electrophoretic analysis and
at levels comparable to endogenous H-2Kk molecules. The fact
that the H-2Ld molecules are serologically detectable on 8-5
cells indicates that they are expressed on the cell surface. In the
following experiments, we applied functional criteria to assess
the capacity of this antigen to mediate cell-cell interactions.
In the first experiment, alloreactive CTLs were generated
in the combinations C3H anti-BALB/c (H-2d specific) and
BALB/c anti-C3H (H-2k specific). These CTLs were then
tested for their ability to kill 51Cr-labeled P815 (H-2d) cells,
Ltk- cells transformed with the herpesvirus tk gene only (Ltk+
cells), or Ltk- cells cotransformed with the tk gene and genomic
clone 27.5 containing the H-2Ld gene (8-5 cells). Although P815
cells were lysed only by H-2d-specific effectors and Ltk+, by
H-2k-specific effectors, 8-5 cells were killed efficiently by both
H-2k- and H-2d-specific effector cells (Fig. 1). Thus, 8-5 cells
appear to express an H_2d gene product (presumably H-2Ld) as
well as endogenous H-2k molecules capable of functioning as
target antigens for CTLs.
To test rigorously the specificity of CTL killing on 8-5, ef-
fector cells specific for either K end molecules or D end mol-
ecules were produced by using various intra-H-2 recombinant
strains. B10. D2 targets (H-2d) were effectively killed by both
Kd_ and Dd/Ld- as well as whole H-2d-specific effectors (Fig.
2). In contrast, 8-5 cells were recognized by CTL specific for
Dd/Ld products but not Kd products. None of the H-2d-specific
effectors were cytotoxic for Ltk+.
Because there are no known recombinants between D and
L, it was not possible to distinguish between D- and L-specific
killing in the previous experiments. However, there exists a
BALB/c mutant strain, C-H-2dm2, that appears to be a loss
mutant for expression of H-2L and H-2R molecules but has re-
tained the H-2D molecule (6). By generating C-H-2`2' anti-
BALB/c effectors it is possible to produce a detectable Ld/Rd_
specific CTL response (12). The results of this experiment are
shown in Fig. 3. Significant killing was seen when C-H-2dm2
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FIG. 1. Ability of 8-5 cells to serve as targets for H-2d-specific CTLs. C3H anti-BALB/c effectors (e) or BALB/c anti-C3H effectors (A) were
assayed on P815 (a), Ltk' (b), or 8-5 (c) targets in a 4-hr 51Cr release assay.
anti-BALB/c effectors were tested on both B10.A and 8-5 tar-
gets. However, no cytotoxicity was observed on Ltk' or
B10.OH targets. This demonstrates the recognition of Ld mol-
ecules on 8-5 cells by a restricted population of effector cells.
Unlabeled Target Inhibitions. Further specificity mapping
was performed by using the technique of unlabeled target in-
hibition. With this approach, CTL lysis of a 5"Cr-labeled target
cell can be inhibited competitively when unlabeled cells ex-
pressing the same target antigens are added in the assay. This
technique has the advantage of avoiding potential ambiguities
resulting from the use of different populations of effector cells.
In this experiment, only one population of effector cells was
used, B10.K anti-B10. D2. Because this combination produces
a mixture of CTL with specificity for H-2Kd, -Dd, or -LU, they
can be used to lyse either B10.OH targets (due to the expression
of Kd) or 8-5 target cells (presumably due to expression of Ld).
B10.K anti-BlO.D2 effector cells were assayed on B10.OH or
8-5 target cells at a constant effector/target ratio of 50:1, with
varying numbers of unlabeled blockers. B1O.A(18R) and A.AL,
both ofwhich express H-2Ld and -Rd but not -Kd were effective
inhibitors of 8-5 lysis but not B10.OH lysis (Fig. 4). In contrast,
B10.OH cells (Kd, Dk) did not inhibit the lysis of 8-5 cells but
did inhibit B10.OH lysis. B10. D2 cells (Kd, Dd) were effective
inhibitors for both targets. These results also demonstrate that
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the target antigens being recognized on 8-5 cells, even by whole
H-2-specific effectors, map to the D region of the H-2 complex.
Complement-Mediated Cytotoxicity. H-2Ld molecules on
the surface of 8-5 cells have been identified by monoclonal
antibody-mediated binding of "2I-labeled protein A (4). The
results shown in Table 2 indicate that the presence of 8-5 cell-
associated H-2Ld determinants can also be detected by com-
plement-mediated cytotoxicity. Confirming the earlier results,
8-5 cells were efficiently lysed by the H-2Ld-reactive mono-
clonals 28-14-8S and 30-5-7S whereas Ltk' cells were not killed.
In addition, a third H-2Ld-reactive monoclonal, 4-9.4, was se-
lectively reactive with clone 8-5. Three monoclonals with con-
firmed H-2Kd activity did not kill either 8-5 cells or Ltk' cells
whereas an H-2Kk-reactive reagent, 7-16.32, effectively lysed
both targets. The 8-5 transformants and normal BALB/c spleen
cells express similar levels of H-2Ld as determined by bind-
ing studies (4). The present results, indicating that all three H-
2Ld-reactive monoclonals have similar cytotoxic titers on 8-5
and BALB/c spleen cells, support this conclusion.
Antibody Blocking of CTL. Finally, we investigated the
blockade of CTL lysis of 8-5 cells by antibodies to H-2Ld mol-
ecules. BIO.K anti-BlO.D2 effector cells were assayed on
B10.OH or 8-5 targets in the continuous presence of varying
dilutions of antisera or monoclonal antibodies. An H-2Ld-spe-
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FIG. 2. Susceptibility of 8-5 targets to lysis by effector cells with restricted specificities. anti-H-2d, B1O.K anti-BlO.D2 (d), anti-H-2DdLd, B1O.K
anti-BlO.A (A), anti-H-2Kd, B1O.A anti-BlO.D2 (a), or anti-H-2k, BMO.D2 anti-BlO.K (A) effector cells were assayed on B1O.D2 (a), Ltk' (b), or 8-5
(c) targets.
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FIG. 3. Susceptibility of 8-5 cells to lysis by mutant anti-BALB/
c effectors. C-H-2dm2 anti-BALB/c effectors were assayed on 8-5 (9),
B10.A (KkDdLd) (A), Ltk+ (Kk,D') (0), or B10.OH (Kd,Dk) (A) targets.
cific antiserum, C-H-2dm2 anti-BALB/c, and an H-2Ld-specific
monoclonal, 28-14-8S, significantly inhibited lysis of8-5 targets
but no inhibition by these reagents was seen with B10.OH tar-
gets (Fig. 5). Interestingly, another H-2Ldspecific monoclonal,
4-9.4, failed to show significant inhibition of 8-5 lysis. Because
4-9.4 did show reactivity toward 8-5 cells in complement-de-
pendent cytotoxicity assays (Table 2), its inability to block CTL
recognition may reflect a specificity on the H-2Ld molecule not
seen readily (or at least in high frequency) by the CTL.
DISCUSSION
We have provided direct evidence for the functional expression
ofa cell surface recognition molecule, H-2Ld, derived by DNA-
mediated gene transfer. The H-2L molecule and the -K and
-D molecules, are polymorphic 45,000-dalton glycoproteins
that function as specific-recognition structures for CTLs (1, 2).
The data in this paper demonstrate that foreign H-2Ld mole-
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Table 2. Cytotoxic activity of H-2Ld-specific monoclonals
on 8-5 cells
Reciprocal cytotoxic titer with
Relevant various target cellst
Monoclonal* activity BALB/c H-2dn2 B1O.K Ltk+ 8-5
5-7.1 Kd 80 160 - - -
7-30.2 Kd 80 80 - - -
6-27.10 Kd 640 ND - - -
7-16.32 Kk - - 640 160 160
4-9.4 Ld 40 - - - 80
28-14-88 Ld 2,048 - ND - 1,024
30-5-7S Ld 16,384 ND ND - 16,384-
* Monoclonals 28-14-8S and 30-5-7S were from ascites fluid; the re-
mainder were from culture supernatants.
t BALB/c, C-H-2dm, and B1O.K targets were mesenteric lymph node
cells. -, No cytotoxicity above the complement background levels
was detected; ND, not done.
cules expressed by cells transformed with the H-2Ld gene are
specifically recognized by CTLs and that this recognition trig-
gers the sequence of events that results in lysis of 8-5 target
cells.
The specificity of the CTL response against 8-5 cells was ver-
ified independently by using D region limited killers, unlabeled
target inhibition, and monoclonal antibody inhibition. The D
region of the H-2d haplotype appears to code for at least four
molecules-D, L, R, and M (6, 13). Because there are no re-
combinants among these genes, it was not possible to distin-
guish among D-, L-, R-, and M-specific killing by using D-re-
stricted killers or unlabeled target inhibition although these
experiments localized the specificity to the D region. However,
further specificity was achieved by using the loss mutant C-H-
2dm2, which fails to express both H-2L and H-2Rd molecules
(6). C-H-2dm2 anti-BALB/c effectors specifically lysed 8-5 cells,
thus narrowing the specificity down to the H-2Ld or Rd mole-
cule. Finally, monoclonal antibody inhibition experiments
showed that two H-2Ld specific monoclonals could almost com-
pletely block CTL recognition and lysis of 8-5 cells, thereby
demonstrating that the relevant CTL target antigen on 8-5 cells
is, in fact, the H-2Ld molecule. In no case was H-2d-specific
killing detected on Ltk+ cells, indicating that the transfection
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FIG. 4. Unlabeled target inhibition of H-2d-specific CTL on 8-5 targets. B1O.K anti-B10.D2 effectors were assayed on B10.OH (Kd, Dk) (a) or
8-5 (b) targets at an effector/target ratio of 50:1 in the presence or absence of various numbers of unlabeled Con A blasts derived from B10.OH
(e), B1O.D2 (A), B1O.A(18R) (Kb,Dd,Ld) (o), or A.AL (Kk,D¶,Ld) (A). Percentage lysis of targets in the absence of blockers was 46% for B10.OH targets
and 40% for 8-5 targets.
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FIG. 5. Antisera/monoclonal antibody inhibition of H-2d-specific effector cells. B1O.K anti-B1O.D2 effector cells were assayed on B10.OH (a)
or 8-5 (b) targets at an effector/target ratio of 50:1, in the presence or absence of varying dilutions of (AxB1O)Fl anti-B1O.D2 (e), 28-14-8S (o),
C-H-2dn"2 anti-BALB/c (o), 7-16.20 (A), 7-16.32 (A), and 4-9.4 (A). Percentage lysis of targets in the absence of antisera was 46% for B10.OH and
40% for 8-5 targets.
procedure itself did not result in expression of H-2d specificities.
We also demonstrated that H-2Ld molecules expressed on
8-5 cells can serve as targets for antibody-dependent comple-
ment-mediated lysis. Three H-2Ld-specific monoclonals were
selectively cytotoxic on 8-5 cells but were unreactive with Ltk'
cells. One monoclonal reagent, 4-9.4, was specifically cytotoxic
for 8-5 cells but failed to block significantly their lysis by CTLs,
even at a concentration well above its cytotoxic titer. This may
reflect a serologic specificity on the Ld molecule not efficiently
recognized by CTLs. Alternatively, the concentration of 4-9.4
antibody used may not have been sufficient to bind with enough
of the available H-2Ld molecules to block their recognition by
CTLs completely. Monoclonal antibodies with similar CTL
blocking properties have been reported by Weyand et al. (14)
for other MHC antigens.
The successful transfer and functional expression of a cloned
gene coding for cell-surface recognition molecules provides a
powerful approach for study of the structure-function relation-
ships of these molecules. Thus, it is now technically possible
to produce, by in vitro recombination and site-directed muta-
genesis, molecules that have precisely defined alterations in the
sequence. With these novel H-2 molecules, it will be possible
to evaluate the effects of these alterations on the functional
expression of the gene products. By using these techniques,
H-2 molecules with known sequence deletions or substitutions
of entire domains or of single amino acids can be produced. It
then will be possible to map the areas of the H-2 molecules that
are responsible for CTL recognition. It will also be possible to
determine if H-2 molecules, like immunoglobulins, have do-
mains specialized for different biological functions.
Finally, the technique should prove useful for the identifi-
cation of genes coding for cell-surface products with similar
structures and for the determination of their function. By using
monoclonal antibodies and MHC-specific T-cell clones to ana-
lyze transformants expressing different cloned genes, it will be
possible to assess the true diversity of functional MHC mole-
cules and to probe the fine structure of the H-2 gene complex.
We thank Drs. David Sachs and Ted Hansen for some of the mono-
clonal antibodies and antisera used in these studies. We thank Dr.
Roger Melvold for supplying the C-H-2dm2 mice. This work was sup-
ported by National Institutes ofHealth Grants CA 22662 and GM 06965.
J.G.W. is a recipient of a National Arthritis Foundation Postdoctoral
Fellowship; R.C.H. is supported by National Research Service Award
NS-07149; R. S. G. is a Senior Lievre Fellow of the California Division
of the American Cancer Society; J.A. F. is the recipient of an American
Cancer Society Faculty Research Award.
1. Dougherty, P. C. & Zinkernagel, R. M. (1975) J. Exp. Med. 141,
502-507.
2. Shearer, G. M. (1974) Eur. J. Immunol 4, 527-533.
3. Steinmetz, M., Moore, K. W., Frelinger, J. G., Taylor-Sher, B.,
Shen, F. W., Boyse, E. A. & Hood, L. (1981) Cell 25, 683-692.
4. Goodenow, R. S., McMillan, M., Orn, A., Nicholson, M.,
Davidson, N., Frelinger, J. A. & Hood, L. (1982) Science 215,
677-679.
5. Ozato, K., Hansen, T. H. & Sachs, D. H. (1980)J. Immunol 125,
2473-2477.
6. Hansen, T. H., Ozato, K., Melino, M. R., Coligan, J. E., Kindt,
T. J., Jandinski, J. J. & Sachs, D. H. (1981) J. Immunol 126,
1713-1716.
7. Harmon, R. C., Shigekawa, B., Stein, N. M. & Frelinger, J. A.
(1982) in Hybridomas in Cancer Diagnosis and Treatment, eds.
Oettgen, H. R. & Mitchell, M. S. (Raven, New York), pp. 21-30.
8. David, C. S., Shreffler, D. C. & Frelinger, J. A. (1973) Proc.
Natl Acad. Sci. USA 70, 2509-2514.
9. Klein, J., Hauptfeld, V. & Hauptfeld, M. (1975) Immunogenetics
2, 141-150.
10. Peck, A. B. & Bach, F. H. (1973) J. Immunol Methods 3,
147-163.
11. Moore, K. W., Taylor-Sher, B., Sun, Y. H., Eakle, K. & Hood,
L. (1982) Science 215, 679-682.
12. Levy, R. B. & Hansen, T. H. (1980) Immunogenetics 10, 7-17.
13. Ivanyi, D. & Demant, P. (1979) Immunogenetics 8, 539-550.
14. Weyand, C., Hammerling, G. J. & Goronzy, J. (1981) Nature
(London) 292, 627-629.
Immunology: Woodward et al.
0
